Conclusions: MELD-Na score was higher in non- survivor group with good predictability for in-hospital mortality and there was good correlation between both the scores in terms of degree of agreement and MELD-Na score was more sensitive compared to MELD score. However, MELD score has better specificity (60%) compared to MELD-Na score (43.3%) at the same cut off value. IMPORTANT We’ve updated and combined our MELD scores into one page. MELD-Na score has better sensitivity (90%) compared to MELD score (80%) at a cut off value above 22. MELDNa/MELD-Na Score for Liver Cirrhosis Adds sodium to the MELD model for liver cirrhosis. In the non- survivor group majority of patients had score of more than 20 (80%). Majority of the patients in survivor group had MELD score between 10-19 (43.3%) and 30-39 (36.7%). The Model of End-stage Liver Disease, or MELD score is used to estimate relative disease severity and likely survival of patients awaiting liver transplantation. The mean MELD score and MELD-Na score was found to be higher in non- survivors group (28.5 and 30.5) compared to survivors group (22.03 and 25.67) which was statistically very significant. The average age was 44.7☑2.040 years in the survivor group and 54.1☙.910 years in the non- survivor group. Results: Out of 50 participants, 20 (40%) died in the hospital due to cirrhosis related complications. MELD score and Model for End Stage Liver Disease-Na (MELD-Na) score was calculated and compared between the groups. Adding serum sodium (MELD-Na) increased the accuracy of the score in predicting waiting. Study population was divided into survivor and non- survivor groups. Its calculation was based on serum bilirubin, serum creatinine. Methods: This is an observational study conducted on 50 patients of ESLD admitted from October 2012 to September 2014. Incorporating serum sodium into MELD score increases its predictive accuracy. Hyponatremia is the most common electrolyte abnormality in End Stage Liver Disease (ESLD). It is calculated according to the following formula: MELD. La puntuación del modelo de enfermedad hepática terminal (Model for end-estage liver disease, MELD) se usa para calcular la gravedad relativa de la enfermedad y la probable supervivencia de pacientes a la espera de trasplante hepático. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. ABSTRACT Background: Model for End-stage Liver Disease (MELD) score was originally developed to predict mortality after trans jugular intrahepatic portosystemic shunt. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing the severity of. MELDNa Score for End-Stage Liver Disease (NOT appropriate for patients under the age of 12) / In these topics.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |